



RECEIVED

DEC 07 1999

TECH CENTER 1600/2900

Docket No. W1068/20011

PATENT

GAU 1614  
#6  
1-4-00  
[Signature]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
PATENT EXAMINING OPERATION

Applicant	:	Kenneth Weisman and Michael E. Goldberg
Serial No.	:	09/089,583
Filed	:	June 3, 1998
For	:	METHOD OF DECREASING ATHEROSCLEROSIS AND ITS COMPLICATIONS
Group Art Unit	:	1614

RECEIVED  
DEC 07 / 1999  
TECH CENTER 1600/2900

---

SUPPLEMENTAL RESPONSE

Assistant Commissioner  
for Patents  
Washington, D.C. 20231

Sir:


During the interview held in October of 1999, Alan H. Bernstein represented to the Examiners that the claims in this application were not intended to cover and in fact do not cover the prior art concepts of using finasteride, leuprolide, bicalutamide, etc. for the treatment of prostatic carcinoma. Accordingly, Mr. Bernstein, through the undersigned, together with Applicant, reaffirms the foregoing representation. Instead, the claims of the present application are directed to the decreasing of atherosclerosis and its complications.

Respectfully submitted,

CAESAR, RIVISE, BERNSTEIN,  
COHEN & POKOTILOW, LTD.

December 2, 1999

By



Robert S. Silver  
Reg. No. 19,315  
12th Floor, Seven Penn Center  
1635 Market Street  
Philadelphia, PA 19103-2212  
Attorneys for Applicant

CERTIFICATE OF MAILING

I hereby certify that the foregoing AMENDMENT, re application Serial No. 09/089,583 is being deposited with the United States Patent and Trademark Office as First Class Mail, postage prepaid, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, this 2<sup>nd</sup> day of December, 1999.



Robert S. Silver